DOCS INTERNATIONAL UK LIMITED

• ◆

  2 PSCs ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101 Reduced Disclosure Framework

Reporting scope

Standalone (parent only)

Auditor

KPMG Chartered Accountants

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements ("the going concern period").”

Significant events

• “On 31 May 2025, DOCS International B.V. transferred the entire share capital of the Company, being 100 ordinary shares of £1.00 each to ICON Clinical Research Holdings (Ireland) Unlimited Company in exchange for the issuance of 16,179,331 ordinary shares in ICON Clinical Research Holdings (Ireland) Unlimited Company.”
• “On 31 May 2025, ICON Clinical Research Holdings (Ireland) Unlimited Company transferred the entire share capital of the Company, being 100 ordinary shares to ICON Clinical Research (U.K.) Limited in exchange for the issuance of 14,375,574 ordinary shares in ICON Clinical Research (U.K.) Limited.”
• “On 31 May 2025, the Company entered into a business transfer agreement to sell the business and undertakings, including all employees, assets and liabilities of the Company to Pharm Research Associates (UK) Limited in exchange for the issuance of 29,356 ordinary shares in Pharm Research Associates (UK) Limited.”
• “On 2 June 2025, Pharm Research Associates (UK) Limited changed its name to ICON Clinical (UK) Limited.”
• “On 2 June 2025, the Company's registered address changed to 3rd Floor, North & South Wings, 100 Longwater Avenue, Green Park, Reading, Berkshire, RG2 6GP, United Kingdom.”
• “On 27 June 2025, the Company transferred its 29,356 ordinary shares in ICON Clinical (UK) Limited to ICON Clinical Research (U.K.) Limited for £14,375,574 to be left outstanding as an intercompany loan.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -11.3%

  £28,853,925 → £25,604,295

• Cash

  +38.3%

  £1,108,168 → £1,532,893

• Net assets

  +18.1%

  £6,454,112 → £7,624,945

• Employees

  -11.8%

  425 → 375

• Operating profit

  -10.8%

  £1,709,670 → £1,524,583

• Profit before tax

  -10.6%

  £1,709,670 → £1,528,583

• Wages

  -8.9%

  £19,776,888 → £18,009,924

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers